Importance and Risk Prediction of ABO Blood Group and Rh Factor in Papillary Thyroid Cancer

Source:
By:Authors

DOI: https://doi.org/10.30564/jer.v4i1.4133

Abstract:

Objective: There are limited data in the literature regarding the potentialrelationship between thyroid cancer and ABO blood types and Rh factor.The aim of our study was to investigate whether papillary thyroid cancer(PTC) is associated with blood type.Materials and Methods: The present study included patients who presented to Dicle University Faculty of Medicine between June 2009 andDecember 2020 and were diagnosed with PTC as a result of postoperative(thyroidectomy) histopathological analysis. The control group consisted ofindividuals whose blood type was analyzed at a random blood center.Results: Of the 223 patients diagnosed with PTC, 163 (73.1%) were females and 60 (26.9%) were males. In the comparison of patients based onABO blood types and Rh factor, A Rh positive blood type was found 31%less frequently in the PTC group compared with the control group, and thusit was associated with a lower risk of PTC (OR:0.69; 95% Confidence Interval: 0.50–0.96, p=0.029).Conclusions: In our study, we found A Rh positive blood type to be significantly less frequent among patients with PTC. A Rh positive blood type canbe considered as a protective factor indicating a reduced risk of PTC.

References:

[1] Gallardo, E., Medina, J., Sánchez, J.C., Viúdez, A., Grande, E., Porras, I., Ramón, Y., Cajal, T., Trigo,J., Iglesias, L., Capdevila, J., 2020. SEOM clinical guideline thyroid cancer. Clin Transl Oncol. 22(2), 223-35. [2] Fagin, J.A., Wells, S.A.Jr., 2016. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med. 375(11), 1054-67. [3] Haugen, B.R., Alexander, E.K., Bible, K.C., et al., 2016. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 26(1), 1-133. [4] Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L.D., Newbold, K., Papotti, M.G., Berruti, A., 2019. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 30(12), 1856-83. [5] Cabanillas, M.E., McFadden, D.G., Durante, C., 2016. Thyroid cancer. Lancet. 388(10061), 2783-95. [6] Pellegriti, G., Frasca, F., Regalbuto, C., Squatrito, S., Vigneri, R., 2013. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 965212. [7] Schneider, D.F., Chen, H., 2013. New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin. 63(6), 374-94. [8] Ain, K.B., 1995. Papillary thyroid carcinoma. Etiology, assessment, and therapy. Endocrinol Metab Clin North Am. 24(4), 711-60. [9] Sadeghi, H., Rafei, M., Bahrami, M., Haghdoost, A., Shabani, Y., 2018. Attributable risk fraction of four lifestyle risk factors of thyroid cancer: a meta-analysis. J Public Health (Oxf). 40(2), e91-e98. [10] Seib, C.D., Sosa, J.A., 2019. Evolving Understanding of the Epidemiology of Thyroid Cancer. Endocrinol Metab Clin North Am. 48(1), 23-35. [11] Dzieczkowski, J.F., Anderson, K.C., 2011. Transfusion Biology and Therapy. Harrison’s Principles of Internal Medicine. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J (eds). 18th ed. New York. McGraw-Hill Education. (1), 951-7. [12] Franchini, M., Liumbruno, G.M., Lippi, G., 2016. The prognostic value of ABO blood group in cancer patients. Blood Transfus. 14(5), 434-40. [13] Rummel, S.K., Ellsworth, R.E., 2016. The role of the histoblood ABO group in cancer. Future Sci OA. 2(2), FSO107. [14] Tam, A.A., Özdemir, D., Fakı, S., Bilginer, M.C., Ersoy, R., Çakır, B., 2020. ABO Blood Groups, Rh Factor, and Thyroid Cancer Risk: To ‘B’ or Not to ‘B’.Endocr Res. 45(2), 137-46. [15] Nix, P., Nicolaides, A., Coatesworth, A.P., 2005. Thyroid cancer review 2: management of differentiated thyroid cancers. Int J Clin Pract. 59(12), 1459-63. [16] Mansour, A., Mohammed, M.A., Anwar, R., Elzafrany, M., Omar, N.M., 2014. ABO blood group and risk of malignancies in Egyptians. Int J Cancer Res. 10(2), 81-95. [17] Huang, J.Y., Wang, R., Gao, Y.T., Yuan, J.M., 2017. ABO blood type and the risk of cancer - Findings from the Shanghai Cohort Study. PLoS One. 12(9), e0184295. [18] Kumar, S., Modak, P.K., Ali, S.H., Barpanda, S.K., Gusain, V.S., Roy, R., 2018. A retrospective study: ABO and Rh phenotype blood group distribution among blood donors in H.N.B. Base Hospital, Srinagar, Uttarakhand, India. J Family Med Prim Care. 7(1), 34-8. [19] Temiz, H., Altıntaş, A., Gül, K., 2008. Distribution of ABO and Rh Blood Groups in Diyarbakir. International Journal of Hematology and Oncology. 4(18), 234-7. [20] Ito, N., Yokota, M., Nagaike, C., Morimura, Y., Hatake, K., Tanaka, O., Matsunaga, T., 1996. Simultaneous expression of keratan sulphate epitope (a sulphated poly-N-acetyllactosamine) and blood group ABH antigens in papillary carcinomas of the human thyroid gland. Histochem J. 28(9), 613-23. [21] González-Cámpora, R., García-Sanatana, J.A., Jordà i Heras, M.M., Salaverri, C.O., Vázquez-Ramírez, F.J., Argueta-Manzano, O.E., Galera-Davidson, H., 1998. Blood group antigens in differentiated thyroid neoplasms. Arch Pathol Lab Med. 122(11), 957-65. [22] Yokota, M., Ito, N., Hirota, T., Yane, K., Tanaka, O., Miyahara, H., Matsunaga, T., 1995. Histochemical differences of the lectin affinities of backbone polylactosamine structures carrying the ABO blood group antigens in papillary carcinoma and other types of thyroid neoplasm. Histochem J. 27(2), 139-47. [23] Khoshsirat, S., Peyvandi, A.A., Oroei, M., Peyvandi, H., Rezaeifard, A., 2019. The Estimation of Thyroid Cancer Risk based on Type 2 Diabetes Mellitus and ABO Blood Group. Turk J Oncol. 35(1), 64-9.